Table 2.
Characteristic | OR (95% CI) | p-value |
---|---|---|
Age (yr) | ||
≤67 | Reference | |
>67 | 0.89 (0.78–1.01) | 0.0636 |
Chemotherapy | ||
No | Reference | |
Yes | 4.98 (4.17–5.96) | <0.0001* |
Comorbidity score | ||
0 | Reference | |
1 | 0.99 (0.85–1.14) | 0.8738 |
≥2 | 1.28 (1.03–1.60) | 0.0288* |
Distance from facility (mile) | ||
≤11.5 | Reference | |
>11.5 | 0.92 (0.81–1.04) | 0.1650 |
Facility type | ||
Community cancer center | Reference | |
Comprehensive community cancer center | 1.20 (1.00–1.45) | 0.0564 |
Academic/research program | 1.35 (1.11–1.63) | 0.0026* |
Grade | ||
Well differentiated | Reference | |
Moderately differentiated | 1.05 (0.90–1.23) | 0.5281 |
Poorly differentiated | 1.24 (0.99–1.54) | 0.0572 |
Education (% without a high school diploma) | ||
≥29 | Reference | |
20–28.9 | 1.03 (0.88–1.20) | 0.7366 |
14–19.9 | 0.98 (0.81–1.17) | 0.8012 |
<14 | 0.92 (0.74–1.14) | 0.4556 |
Median income by zip code (US dollar) | ||
<30,000 | Reference | |
30,000–34,999 | 0.99 (0.83–1.17) | 0.8681 |
35,000–45,999 | 0.98 (0.81–1.18) | 0.7918 |
≥46,000 | 1.17 (0.95–1.44) | 0.1376 |
Insurance | ||
None | Reference | |
Private | 0.81 (0.62–1.06) | 0.1278 |
Government | 0.82 (0.62–1.08) | 0.1614 |
Location | ||
Metropolitan | Reference | |
Urban | 1.21 (1.02–1.42) | 0.0274* |
Rural | 1.25 (0.87–1.80) | 0.2266 |
Race | ||
Caucasian | Reference | |
African American | 0.89 (0.74–1.06) | 0.1800 |
Other | 1.08 (0.78–1.48) | 0.6499 |
Gender | ||
Male | Reference | |
Female | 1.12 (0.97–1.30) | 0.1288 |
Stage | ||
Tis | Reference | |
T1 | 0.93 (0.77–1.13) | 0.4665 |
T2 | 2.12 (1.74–2.59) | <0.0001* |
Year group | ||
2004–2006 | Reference | |
2007–2009 | 3.25 (2.63–4.01) | <0.0001* |
2010–2012 | 5.10 (4.16–6.25) | <0.0001* |
2013–2015 | 5.94 (4.86–7.28) | <0.0001* |
Dose per fraction (Gy) | ||
≤2.0 | Reference | |
>2.0 | 0.78 (0.70–0.88) | <0.0001* |
IMRT, intensity-modulated radiation therapy; OR, odds ratio; CI, confidence interval.
Bold font indicates statistical significance.
p < 0.05, statistical significance.